Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Stanford University
Alpha-9 Oncology USA Inc.
Fred Hutchinson Cancer Center
Ankyra Therapeutics, Inc
MonTa Biosciences ApS
ViroMissile, Inc.
Pfizer
Pfizer
Tizona Therapeutics, Inc
Werewolf Therapeutics, Inc.
MacroGenics
ModernaTX, Inc.
Adaptimmune
OncoNano Medicine, Inc.
City of Hope Medical Center
Memorial Sloan Kettering Cancer Center
AccSalus Biosciences, Inc.
Abramson Cancer Center at Penn Medicine
Modulation Therapeutics, Inc.
M.D. Anderson Cancer Center
Incyte Corporation
TuHURA Biosciences, Inc.
Memgen, Inc.
Pfizer
Leap Therapeutics, Inc.
University of California, San Diego
Biogen
Scholar Rock, Inc.
Altor BioScience
Pfizer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
Pliant Therapeutics, Inc.
Eli Lilly and Company
University of California, San Francisco
TopAlliance Biosciences
Adaptimmune
Rutgers, The State University of New Jersey
Perspective Therapeutics
Providence Health & Services
Seagen Inc.
Herlev Hospital
Quadriga Biosciences, Inc.
Provectus Pharmaceuticals
Pfizer
University of Kansas Medical Center
Novartis